Eccogene Receives $50M Milestone After Elecoglipron Phase 3 Start
BOSTON and SHANGHAI — September 28, 2026 Eccogene announced that it has received a $50 million milestone payment from...
Obesity
Advertisement
Wave Initiates Phase 2a WVE-007 Combination Trial for Obesity
CAMBRIDGE, Mass. — September 23, 2026 Wave Life Sciences announced the initiation of a Phase 2a clinical trial evaluating...
Rhythm Gains Health Canada Approval for IMCIVREE in HO
BOSTON — September 22, 2026 Rhythm Pharmaceuticals announced that Health Canada has approved IMCIVREE® (setmelanotide) for weight management in...
Artelo Files Patent for ART27.13 in Obesity
SOLANA BEACH, Calif. — September 23, 2026 Artelo Biosciences announced that it has filed a new provisional patent application...
Viking Therapeutics Reports Positive VK2735 Weight Results
San Diego, California, U.S., September 22, 2026 Viking Therapeutics, Inc. has announced positive topline results from a maintenance study...
Advertisements
Zealand Pharma Initiates Phase 3 ZUPREME Program for Petrelintide
COPENHAGEN, Denmark — September 22, 2026 Zealand Pharma announced the initiation of the global registrational Phase 3a ZUPREME program...
Novo Nordisk Reports Positive Phase 3 CagriSema Resultsx
Bagsværd, Denmark, September 21, 2026 Novo Nordisk has announced topline results from two Phase 3 trials evaluating CagriSema, an...
MitoRx to Present MTRX31 Obesity Data at EASD 2026
HARWELL, Oxford, UK — September 17, 2026 MitoRx Therapeutics announced that new data for its lead mitochondrial-targeted small molecule...
Syntis Bio Advances Oral SYNT-101 Toward Phase 2
BOSTON — September 15, 2026 Syntis Bio, Inc. announced results from the 28-day multiple-ascending-dose (MAD) portion of its Phase...
Novo Nordisk Launches Novo Rebrand and New Corporate Culture
BAGSVAERD, Denmark — September 14, 2026 Novo Nordisk A/S announced the launch of a new corporate brand centred on...
Advertisement
